


CORRECTION

Correction: Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms

Marius Ilie, Shirin Khambata-Ford, Christiane Copie-Bergman, Lingkang Huang, Jonathan Juco, Veronique Hofman, Paul Hofman

[Fig 1](#) is incorrect. The authors have provided a corrected version here.



OPEN ACCESS

Citation: Ilie M, Khambata-Ford S, Copie-Bergman C, Huang L, Juco J, Hofman V, et al. (2017) Correction: Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms. PLoS ONE 12 (10): e0186537. <https://doi.org/10.1371/journal.pone.0186537>

Published: October 13, 2017

Copyright: © 2017 Ilie et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Fig 1. Optimised protocols for PD-L1 IHC assays using the 22C3 antibody concentrate on the Dako ASL48 and VENTANA BenchMark ULTRA platforms. PD-L1, programmed death ligand 1; IHC, immunohistochemistry; ASL48, Autostainer Link 48; DAB, 3,3'-diaminobenzidine tetrahydrochloride.

<https://doi.org/10.1371/journal.pone.0186537.g001>

Reference

1. Ilie M, Khambata-Ford S, Copie-Bergman C, Huang L, Juco J, Hofman V, et al. (2017) Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms. PLoS ONE 12(8): e0183023. <https://doi.org/10.1371/journal.pone.0183023> PMID: 28797130